LANSING, Mich., July 30, 2014 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) ("Company"), the leading developer of advanced spider silk based fibers, announces that research scientists who are working as consultants for the Company have recently implemented a new materials analysis protocol to further improve the quality of the Company's genetically engineered spider silk based fibers.
The scientists tested the new procedures and are now using them to test individual fiber filaments. The innovation allows Kraig to gather testing data on its transgenics even before the transgenics reach the stage where they are spinning cocoons. This early testing data is then incorporated into the decision making process, regarding artificial selection and selective breeding. The new process means the research team can assess, and then make adjustments to variations in, the silk colony, reduce variability, and, the Company believes, further increase the quality of its recombinant fiber production.
"One of the biggest issues we have faced, as we focus on moving our materials to market, is natural variability between individual fiber filaments. This new protocol and procedure is a significant breakthrough that will allow us to improve quality, while reducing variability. Overcoming this major hurdle has a direct impact in the laboratory and the commercial ramp up program," said Company founder and CEO, Kim K. Thompson. "I want to thank the scientists who have implemented and are perfecting this protocol, which we believe will have a real impact on our commercialization program." Thompson concluded.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
CONTACT: Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc